GPR87 and lung adenocarcinoma: Therefore, although we did not perform the experiments in this study, we expect that the combination of a GPR87 inhibitor with an eNOS inhibitor can serve as an attractive therapeutic strategy to achieve clinical benefits in lung adenocarcinoma.